| 1 |
34728570 | Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer. | 2022 Jan |
1 |
| 2 |
35385726 | Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. | 2022 Apr 5 |
1 |
| 3 |
33771885 | Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. | 2021 Jun |
1 |
| 4 |
31587305 | Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide. | 2020 Apr |
2 |
| 5 |
31822380 | TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. | 2020 Apr |
1 |
| 6 |
30209161 | TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. | 2019 Mar 15 |
1 |
| 7 |
31046065 | Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. | 2019 Jul 1 |
1 |
| 8 |
31297844 | The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells. | 2019 Oct |
1 |
| 9 |
29302046 | p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. | 2018 Jun |
1 |
| 10 |
28228262 | Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. | 2017 Feb 21 |
2 |